Visão geral da empresa
OmniAb, Inc. operates within the healthcare sector, specifically functioning as a biotechnology entity that licenses its proprietary discovery research technology to pharmaceutical companies, biotech firms, and academic institutions globally. This business model enables the identification of therapeutics across key markets including the United States, Europe, Japan, China, and Canada, leveraging a technology platform designed to create and screen diverse candidates. The company currently maintains a market capitalization of $218.62M and employs a workforce of 89 individuals to execute its licensing strategy. With an annual revenue of $18.67M, the firm operates as a micro-cap entity, indicating a specialized position in the biotech value chain where value is derived from intellectual property licensing rather than direct product sales or large-scale manufacturing operations.
Saúde financeira
OmniAb, Inc. reported a trailing twelve-month revenue of $18.67M, while simultaneously recording a net income of -$64,779,000 and an EBITDA of -$46,890,000. The substantial disparity between the positive revenue figure and the significant negative net income reveals a cost structure where operating expenses far exceed revenue generation, a common characteristic in early-stage biotechnology firms focused on research and development. The company's free cash flow stands at -$8,670,000, which indicates that current operational activities are consuming cash reserves rather than generating liquidity, thereby limiting immediate financial flexibility for non-core expenditures. Analysis of the profit margins shows a gross margin of 98.4%, suggesting highly efficient production or licensing of the technology itself, yet an operating margin of -147.3% and a profit margin of 0.0% highlight severe structural losses before interest and taxes. Regarding balance sheet leverage, the firm holds $54.02M in cash against $20.33M in debt, resulting in a debt-to-equity ratio of 7.62, which suggests a leveraged position where equity is relatively small compared to total liabilities. However, the current ratio of 4.02 indicates robust short-term liquidity, as the company possesses more than four times the current assets necessary to cover its short-term obligations. Furthermore, the return on equity is -23.4% and the return on assets is -13.0%, metrics that reveal management is currently generating negative returns on the capital invested by shareholders and utilized in assets.
Avaliação de valorização
The valuation metrics for OmniAb, Inc. include a P/E ratio (TTM) that is listed as N/A due to negative earnings, while the forward P/E is reported as -5.03. The distinction between these figures, particularly the negative forward P/E, implies that analysts or models are projecting continued negative earnings in the near term rather than anticipating immediate profitability. The price-to-book ratio is 0.82, indicating that the company's market capitalization trades at a discount to its book value, suggesting the market values the firm's assets conservatively or anticipates challenges in realizing that book value. Alternative valuation measures such as the price-to-sales ratio of 11.71 and an EV/EBITDA of -3.94 provide additional context, suggesting that the market is pricing the company based on revenue multiples rather than earnings power, which is typical for biotech firms with high growth potential but current losses. In terms of trading range, the stock has a 52-week high of $2.57 and a 52-week low of $1.22. Without a specific current price provided in the facts, the valuation assessment relies on the context that the stock trades within this volatility band, with the high representing the peak market sentiment over the last year. The beta value is 0.85, which indicates that the stock's price volatility is slightly lower than the broader market benchmark, suggesting somewhat lower sensitivity to general market fluctuations compared to the average equity.
Growth & Income
The revenue growth year-over-year is -22.5%, while earnings growth is N/A due to the absence of reported net income in the current period. Since earnings are currently negative, a comparison of growth rates between revenue and earnings is not mathematically applicable, but the decline in revenue suggests a contraction in licensing activity or market demand over the last year. The company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the firm does not return cash to shareholders, and instead, the capital is retained to fund ongoing research, development, and operational needs typical of the biotechnology sector. The overall growth and income profile is characterized by negative revenue momentum and a complete lack of current income generation or dividend distribution, reflecting the high-risk, long-cycle nature of the biotech industry where capital is prioritized for future asset creation rather than current shareholder returns.